Dyne therapeutics patent
WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on … WebAt Leal Health we understand that fighting cancer can be a lonely journey. You might feel like the world is moving on without you. But please know that you're…
Dyne therapeutics patent
Did you know?
WebFeb 28, 2024 · As of February 28, 2024, Dyne Therapeutics Inc had a $681.8 million market capitalization, putting it in the 59th percentile of companies in the Biotechnology & Medical Research industry. Dyne Therapeutics Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. WebApr 3, 2024 · Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace ... Patents Assigned (Count) 4. Other …
WebPatents and Trademarks by IPqwery. The intellectual property of Dyne Therapeutics includes 51 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' … WebDoing Business As: Dyne Therapeutics Company Description: Key Principal: Joshua Brumm See more contacts Industry: Pharmaceutical preparations Printer Friendly View Address: 1560 Trapelo Rd Waltham, MA, 02451-7306 United States Phone: Website: www.dyne-tx.com Employees (this site): Actual Employees (all sites): Actual
WebJul 28, 2024 · February 14, 2024 updated by: Dyne Therapeutics A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1 WebAspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, and/or ACVR1
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically …
WebJun 11, 2024 · Dyne Therapeutics announced the appointment of Daniel Wilson as vice president, head of intellectual property. Contacts Media Ten Bridge Communications … east west north carolinaWebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … cummings home pageWebPatent Counsel jobs Writer jobs Executive jobs ... Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living ... eastwest no annual fee for lifeWebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … east west north south in gujaratiWebDyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva US11168141B2 (en) 2024-08-02: 2024-11-09: … east west office nottinghamWebJan 10, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral... east west north south in bengaliWebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449. cummings home courtenay